Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934878 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL2257134 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14477068 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL13559226 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL20143480 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL16684305 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14072288 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL21007943 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL20693186 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL10062436 | 1.00 | PTPN1 (0.55) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615818-B | Synthesis method of fludarabine and nelarabine | 江西科技师范大学 | 2023-02-17 | — | — | CN | claimed |
| CN-110615818-A | Synthesis method of fludarabine and nelarabine | 江西科技师范大学 | 2019-12-27 | — | — | CN | claimed |
| EP-1172369-B1 | Synthesis of 2-deoxy-2-fluoro-arabinose derivates | AIR PROD & CHEM (US) | 2010-09-22 | — | — | EP | claimed |
| WO-2008069451-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CLEVUDINE AS ANTI-HBV AGENT | BUKWANG PHARM CO., LTD. (KR) | 2008-06-12 | — | — | WO | claimed |
| US-6462191-B1 | DEOXOFLUORINATION OF FURANOSE; HEATING | AIR PRODUCTS AND CHEMICALS, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1172369-A1 | Synthesis of 2-deoxy-2-fluoro-arabinose derivates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2002-01-16 | — | — | EP | claimed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-113929724-B | Nucleoside compound, pharmaceutical composition and application thereof | 周雨恬 | 2024-05-31 | — | — | CN | disclosed |
| US-11981699-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-5565438-A | L-nucleosides for the treatment of epstein-bar virus | UNIVERSITY OF GA RESEARCH FOUNDATION (US) | 1996-10-15 | — | — | US | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995020595-A1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| US-4879377-A | Nucleoside process | BRISTOL-MYERS COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0145978-B1 | NUCLEOSIDE PROCESS | Bristol-Myers Company (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4625020-A | Nucleoside process | BRISTOL-MYERS COMPANY (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0145978-A2 | Nucleoside process | Bristol-Myers Company (US) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PTPN1 2063/4885USP2 4681/4885POLB 16/4885 |
| US-11981699-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, MTAP | PTPN1 3624/4885USP2 4311/4885POLB 52/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PTPN1 2063/4885USP2 4681/4885POLB 16/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | PTPN1 2063/4885USP2 4681/4885POLB 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.